Some of the mainstays of prostate cancer treatment—radiotherapy and androgen deprivation therapy—can also trigger upregulation of CXCR2 ligands, which constitute a part of the senescence-associated secretory phenotype (SASP)10,12,14,23. Here, CXCR2 is linked to prostate carcinoma.